DYNE THERAPEUTICS INC
(NASDAQ: DYN)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

28.380

-0.120 (-0.42%)
Range 27.270 - 29.000   (6.34%)
Open -
Previous Close 28.500
Bid Price 13.190
Bid Volume 12
Ask Price 13.280
Ask Volume 9
Volume 1,321,772
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 03:59.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis